Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Otitis
Interventions: Saline, Fentanyl, Dexmedetomidine; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 6 Months to 6 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Overactive Bladder
Interventions: onabotulinumtoxinA, normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Erectile Dysfunction
Interventions: Autologous Platelet Rich Plasma, Saline solution; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 75 Years · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Meningococcal Vaccines
Interventions: Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Use, Surgical Recovery, Vaginal Hysterectomy, Prolapse Pelvic, Postoperative Pain
Interventions: Bupivacaine-epinephrine, Normal saline; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Cystic Fibrosis
Interventions: N6022, Normal saline; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 17
States / cities: Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more

Conditions: Chronic Kidney Disease; Iron Deficiency Anemia
Interventions: Ferumoxytol, Iron sucrose; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 8
States / cities: Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more

Conditions: Overactive Bladder
Interventions: onabotulinumtoxinA, Normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 40
States / cities: Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 35 more

Conditions: Degenerative Disc Disease
Interventions: IDCT, Saline Solution, Sodium Hyaluronate; Biological · Drug
Lead sponsor: DiscGenics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more

Conditions: Second Stage of Labor
Interventions: Caffeine and Sodium Benzoate Injection, Normal Saline; Drug
Lead sponsor: The Reading Hospital and Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: West Reading, Pennsylvania

Conditions: Acute Kidney Injury
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Le Bonheur Children's Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Chronic Kidney Disease
Interventions: GCS-100, Placebo, Saline; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Tempe, Arizona • La Mesa, California • Denver, Colorado + 1 more

Conditions: Hypogammaglobulinemia, Congenital Heart Disease
Interventions: IVIG, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Up to 6 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Herpes Zoster, Vaccine-Preventable Diseases
Interventions: Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo; Biological · Drug
Lead sponsor: Beijing Luzhu Biotechnology Co., Ltd.; Other
Eligibility: 50 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Bleeding, Bruising Face, Swelling Lips & Face
Interventions: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml, Normal Saline 0.9% Infusion Solution Bag; Drug
Lead sponsor: Glasgold Group Plastic Surgery; Other
Eligibility: 40 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Anesthesia, Local
Interventions: AG-920, Placebo; Drug
Lead sponsor: American Genomics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Newport Beach, California • McAllen, Texas

Conditions: Breast Cancer
Interventions: Tranexamic Acid, Saline; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Postoperative Pain
Interventions: lidocaine (1%) + bupivacaine (0.5%), Normal saline, Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg); Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 3 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Opioid-Related Disorders, Chronic Pain
Interventions: Buprenorphine, Hydromorphone, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome
Interventions: Recommendation: No Further Resuscitation, Recommendation: Resuscitation with Crystalloid, Recommendation: Resuscitation with Colloid, Recommendation: Standard of Care IV Albumin; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Insulin, Asp(B28)-, Glucagon, Placebo; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced Ovarian Cancer
Interventions: AST-201, Paclitaxel, Carboplatin, Placebo, rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor); Biological · Drug
Lead sponsor: Aston Sci. Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pancreatic Carcinoma, Pancreatic Neoplasm
Interventions: Biospecimen Collection, Distal Pancreatectomy, Lanreotide, Questionnaire Administration, Saline; Procedure · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 118
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 93 more

Conditions: Arnold-Chiari Malformation, Posterior Fossa Tumors
Interventions: IV acetaminophen, normal saline; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Dexmedetomidine vs Fentanyl for BMT

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

Paracervical Injection and Opioid Use After Vaginal Hysterectomy for Prolapse

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

Caffeine in the Second Stage of Labor in Low-risk Nulliparous Mothers at Term

Preventing Acute Kidney Injury (AKI) in Pediatric Patients

A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

Post-bypass Prophylactic IVIG in Infants and Neonates

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

Intravenous Tranexamic Acid During Rhytidectomy

A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution

Impact of Topical Tranexamic Acid in Breast Reconstruction

Pediatric Tonsillectomy Pain Reduction Study

Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

Efficacy of Acetaminophen in Posterior Fossa Surgery